loading
Lantern Pharma Inc stock is traded at $3.48, with a volume of 24,481. It is up +2.65% in the last 24 hours and down -6.45% over the past month. Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.39
Open:
$3.39
24h Volume:
24,481
Relative Volume:
0.50
Market Cap:
$37.62M
Revenue:
-
Net Income/Loss:
$-15.16M
P/E Ratio:
-2.6336
EPS:
-1.3214
Net Cash Flow:
$-13.65M
1W Performance:
-7.69%
1M Performance:
-6.45%
6M Performance:
-47.83%
1Y Performance:
+6.42%
1-Day Range:
Value
$3.39
$3.6065
1-Week Range:
Value
$3.30
$3.8699
52-Week Range:
Value
$2.38
$11.99

Lantern Pharma Inc Stock (LTRN) Company Profile

Name
Name
Lantern Pharma Inc
Name
Phone
972-277-1136
Name
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Name
Employee
21
Name
Twitter
@lanternpharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
LTRN's Discussions on Twitter

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-07-21 Initiated H.C. Wainwright Buy

Lantern Pharma Inc Stock (LTRN) Latest News

pulisher
Oct 09, 2024

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Prom - GuruFocus.com

Oct 09, 2024
pulisher
Sep 30, 2024

After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals - Stocks Telegraph

Sep 30, 2024
pulisher
Sep 26, 2024

11 Best AI Penny Stocks Under $10 in 2024 - CoinCodex

Sep 26, 2024
pulisher
Sep 23, 2024

Lantern Pharma secures three new FDA rare disease tags - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Lantern Pharma secures three new FDA rare disease tags - Investing.com India

Sep 23, 2024
pulisher
Sep 23, 2024

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - BioSpace

Sep 23, 2024
pulisher
Sep 23, 2024

Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - Business Wire

Sep 23, 2024
pulisher
Sep 11, 2024

Norton Cancer Institute patient receives first-in-world clinical trial medicine dose - Norton Healthcare

Sep 11, 2024
pulisher
Aug 31, 2024

Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance

Aug 31, 2024
pulisher
Aug 18, 2024

LTRN (Lantern Pharma) EPS (Basic) : $-1.65 (TTM As of Jun. 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 18, 2024

Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Update - Defense World

Aug 18, 2024
pulisher
Aug 17, 2024

LTRN (Lantern Pharma) 50-Day SMA : $4.42 (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

LTRN (Lantern Pharma) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 14, 2024

Q3 2024 Earnings Forecast for Lantern Pharma Inc. (NASDAQ:LTRN) Issued By Zacks Small Cap - Defense World

Aug 14, 2024
pulisher
Aug 12, 2024

LTRN: Second Quarter Results - Yahoo Finance

Aug 12, 2024
pulisher
Aug 10, 2024

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript - Seeking Alpha

Aug 10, 2024
pulisher
Aug 09, 2024

LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan

Aug 09, 2024
pulisher
Aug 08, 2024

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 - MSN

Aug 08, 2024
pulisher
Aug 08, 2024

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - StockTitan

Aug 08, 2024
pulisher
Aug 08, 2024

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - Business Wire

Aug 08, 2024
pulisher
Aug 07, 2024

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Business Wire

Aug 07, 2024
pulisher
Aug 07, 2024

Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Thursday - Defense World

Aug 07, 2024
pulisher
Aug 07, 2024

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Yahoo Finance

Aug 07, 2024
pulisher
Aug 06, 2024

LTRN: Harmonic Clinical Update - Zacks Small Cap Research

Aug 06, 2024
pulisher
Aug 06, 2024

LTRN: Harmonic Clinical Update - Yahoo Finance

Aug 06, 2024
pulisher
Aug 05, 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - Chronicle-Tribune

Aug 05, 2024
pulisher
Aug 05, 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - StockTitan

Aug 05, 2024
pulisher
Aug 05, 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - Business Wire

Aug 05, 2024
pulisher
Aug 01, 2024

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET - Business Wire

Aug 01, 2024
pulisher
Jul 20, 2024

Head-To-Head Analysis: Lantern Pharma (NASDAQ:LTRN) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World

Jul 20, 2024
pulisher
Jul 18, 2024

CASI Pharmaceuticals (NASDAQ:CASI) versus Lantern Pharma (NASDAQ:LTRN) Financial Comparison - American Banking and Market News

Jul 18, 2024
pulisher
Jul 18, 2024

CASI Pharmaceuticals (NASDAQ:CASI) versus Lantern Pharma (NASDAQ:LTRN) Financial Comparison - Defense World

Jul 18, 2024
pulisher
Jul 15, 2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - Marketscreener.com

Jul 15, 2024
pulisher
Jul 15, 2024

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate - Yahoo Finance

Jul 15, 2024
pulisher
Jul 10, 2024

Kintara Therapeutics restructures share designations By Investing.com - Investing.com

Jul 10, 2024
pulisher
Jul 10, 2024

Cosmos Health completes hydrogel development for weight management By Investing.com - Investing.com India

Jul 10, 2024
pulisher
Jul 10, 2024

Netflix shares price target lifted on Q2 earnings report - Investing.com

Jul 10, 2024
pulisher
Jul 10, 2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - Business Wire

Jul 10, 2024
pulisher
Jul 04, 2024

LP-184 synergizes with PARP inhibitor in atypical teratoid rhabdoid tumor - BioWorld Online

Jul 04, 2024
pulisher
Jul 04, 2024

How AI is transforming drug discovery - The Pharmaceutical Journal

Jul 04, 2024
pulisher
Jun 29, 2024

Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Down 20.6% in June - MarketBeat

Jun 29, 2024
pulisher
Jun 29, 2024

Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90 ... - The Globe and Mail

Jun 29, 2024
pulisher
Jun 29, 2024

Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology ... - The Globe and Mail

Jun 29, 2024
pulisher
Jun 27, 2024

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical ... - Quantisnow

Jun 27, 2024
pulisher
Jun 26, 2024

Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - The Globe and Mail

Jun 26, 2024
pulisher
Jun 26, 2024

Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - The Globe and Mail

Jun 26, 2024
pulisher
Jun 26, 2024

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 - The Globe and Mail

Jun 26, 2024
pulisher
Jun 26, 2024

Lantern Pharma Inc (LTRN-Q) QuotePress Release - The Globe and Mail

Jun 26, 2024
pulisher
Jun 25, 2024

, aids in the discovery of DNA damaging agent for the ultra-rare cancer Atypical Teratoid Rhabdoid Tumors - Frontiers

Jun 25, 2024

Lantern Pharma Inc Stock (LTRN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lantern Pharma Inc Stock (LTRN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Fletcher Aaron G.L.
10% Owner
May 23 '24
Sale
6.25
10,000
62,500
59,326
Fletcher Aaron G.L.
10% Owner
Feb 28 '24
Sale
4.85
74,297
360,340
62,088
Fletcher Aaron G.L.
10% Owner
Feb 27 '24
Sale
4.40
50,000
220,000
68,997
Fletcher Aaron G.L.
10% Owner
Feb 29 '24
Sale
4.87
19,703
95,954
60,256
Kreis Leslie W.
10% Owner
Feb 28 '24
Sale
4.85
74,297
360,340
62,088
Kreis Leslie W.
10% Owner
Feb 27 '24
Sale
4.40
50,000
220,000
68,997
Kreis Leslie W.
10% Owner
Feb 29 '24
Sale
4.87
19,703
95,954
60,256
Fletcher Aaron G.L.
10% Owner
Jan 17 '24
Sale
4.20
58,889
247,334
73,646
Kreis Leslie W.
10% Owner
Jan 17 '24
Sale
4.20
58,889
247,334
73,646
Fletcher Aaron G.L.
10% Owner
Nov 29 '23
Sale
3.44
145,348
499,997
217,553
$23.53
price down icon 0.76%
$358.22
price up icon 1.10%
$58.29
price up icon 2.57%
$236.10
price down icon 1.37%
$120.52
price up icon 1.82%
$536.70
price up icon 1.79%
Cap:     |  Volume (24h):